Crossject Société Anonyme (EPA: ALCJ)

Market Cap	84.77M
Revenue (ttm)	2.36M
Net Income (ttm)	-10.48M
Shares Out	42.81M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,175
Open	1.998
Previous Close	2.000
Day's Range	1.954 - 1.998
52-Week Range	1.520 - 5.960
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 24, 2024

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The c...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2001
• Employees: 105
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCJ

Financial Performance

In 2023, Crossject Société Anonyme's revenue was 3.87 million, a decrease of -45.18% compared to the previous year's 7.06 million. Losses were -8.64 million, -22.58% less than in 2022.